The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
Despite the success of liver transplantation, long-term complications remain, including de novo malignancies, metabolic syndrome, and the recurrence of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). The current mainstay of treatment, calcineurin inhibitors (CNIs), can also worsen posttr...
Saved in:
Main Authors: | Goran B. Klintmalm, Björn Nashan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2014/845438 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
by: Jeffrey Campsen, et al.
Published: (2011-01-01) -
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
by: Gianluigi Zaza, et al.
Published: (2013-01-01) -
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment
by: Jiarui Lv, et al.
Published: (2025-01-01) -
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
by: J. Martin-Liberal, et al.
Published: (2014-01-01) -
The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway
by: Danilo Figueiredo Soave, et al.
Published: (2016-01-01)